Cardio3 BioSciences raises €13.7 million
This article was originally published in Scrip
Executive Summary
Cardio3 BioSciences, a Belgian biotechnology company, has raised €13.7 million from private funding and a repayable grant. It specialises in cell-based therapies for the treatment of cardiovascular diseases.